Research Topics
| D MukherjeeSummaryAffiliation: University of Michigan Country: USA Publications
| Collaborators
|
Detail Information
Publications
Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years oldDebabrata Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA
Am J Cardiol 92:1465-7. 2003....- Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndromeD Mukherjee
Division of Cardiology, University of Michigan, Health System, 1500 E Medical Center Drive, Ann Arbor, Michigan 48103 0311, USA
Heart 91:23-6. 2005..To assess a clinically significant interaction between cytochrome P450 3A4 (CYP3A4) metabolised statin and clopidogrel... - Improving quality of cardiovascular care in the real world: how can we remove the barriers?Debabrata Mukherjee
Division of Cardiology, University of Health System, University Hospital, Ann Arbor, Mich 48103-0311, USA
Am J Manag Care 10:471-2. 2004 - Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular eventsDebabrata Mukherjee
Division of Cardiology, University Hospital, University of Michigan Health System, B1 F245, 1500 East Medical Center Drive, Ann Arbor, MI 48103 0022, USA
Biochem Pharmacol 63:817-21. 2002..The widespread popularity of these agents mandates their prospective evaluation in patients with cardiovascular diseases or who are at risk for cardiovascular events... - Current clinical perspectives on myocardial angiogenesisDebabrata Mukherjee
Division of Cardiology, The University of Michigan, Ann Arbor, MI 48109 0311, USA
Mol Cell Biochem 264:157-67. 2004..This review discusses myocardial angiogenesis as a therapeutic modality in these patients including therapeutic angiogenesis with growth factors and cell transplantation... - Percutaneous treatment for carotid stenosisDebabrata Mukherjee
Division of Cardiology, University of Michigan Health System, University Hospital, B1 F245, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0022, USA
Cardiol Clin 20:589-97. 2002.... - Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromesDebabrata Mukherjee
University of Michigan, Ann Arbor, Mich, USA
Circulation 109:745-9. 2004..However, the impact of the combination of these agents on clinical outcomes has not been studied before... - Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2)Debabrata Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor, USA
Circulation 106:1909-12. 2002..Peripheral vascular disease is a manifestation of systemic atherosclerosis and is associated with an increased risk of cardiovascular morbidity and mortality... - Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding riskD Mukherjee
Department of Cardiology, University of Michigan, Ann Arbor, Michigan 48109 0022, USA
J Thromb Thrombolysis 11:151-4. 2001.... - Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later timesFadi A Saab
University of Michigan Cardiovascular Center, Ann Arbor, Michigan 48109-0311, USA
Am J Cardiol 94:1166-8. 2004..Prompt administration of statins appears to be significantly beneficial in patients who present with an acute coronary syndrome... - Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndromeRakesh Latchamsetty
University of Michigan Hospital, Ann Arbor, Michigan, USA
Am J Cardiol 99:939-42. 2007..Furthermore, return to baseline function by discharge does not protect against this risk. These findings have implications for management of these high-risk patients... - Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)Debabrata Mukherjee
University of Michigan Health System, Ann Arbor, Mich, USA
Am Heart J 144:995-1002. 2002..These findings support the rationale and promise for combining GP IIb/IIIa blockers and LMWH for future management of acute coronary syndrome... - The role of low-molecular-weight heparin in cardiovascular diseasesDebabrata Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor, USA
Prog Cardiovasc Dis 45:139-56. 2002.... - Prognostic significance of an elevated creatine kinase in the absence of an elevated troponin I during an acute coronary syndromeKimberly C Yee
Division of Cardiology, Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan, USA
Am J Cardiol 92:1442-4. 2003..This risk is accentuated in troponin-negative, CK-MB positive patients who do not demonstrate ST elevation by electrocardiogram... - Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: how can clinicians reduce the risks?Debabrata Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor, Mich, USA
Am Heart J 148:371-7. 2004 - Update on peripheral vascular diseases: from smoking cessation to stentingD Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor 48109 0022, USA
Cleve Clin J Med 68:723-33. 2001..Nonetheless, the two most important treatments remain the same: stopping smoking and starting a walking program... - Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of diseaseSanjay Rajagopalan
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 0273, USA
Arthritis Rheum 48:1992-2000. 2003..To compare microvascular and macrovascular functions in a cohort of patients with primary and secondary Raynaud's phenomenon (RP) who were matched for demographic, risk factor, and severity profiles... - Variation in outcomes after percutaneous coronary intervention in the United States and predictors of periprocedural mortalityDebabrata Mukherjee
University of Michigan Cardiovascular Center, Ann Arbor, Mich, USA
Cardiology 103:143-7. 2005..Even in the contemporary era of adjunctive pharmacological therapies and ubiquitous use of stents, hospital volume remains a significant independent predictor of in-hospital mortality... - Long-term prognostic implication of extracardiac vascular disease in patients undergoing percutaneous coronary interventionBrahmajee K Nallamothu
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
Am J Cardiol 92:964-6. 2003..0 to 2.0, p = 0.029). When extracardiac vascular disease was separated into cerebrovascular disease and peripheral vascular disease, cerebrovascular disease was less common but was associated with a trend towards worse survival... - Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortalityPeter K Henke
Cardiovascular Division of Medicine, University of Michigan, Ann Arbor, MI, USA
J Vasc Surg 39:357-65. 2004..Whether statin drugs and ACE inhibitors confer an improvement in graft patency, limb salvage, and operative mortality is unknown... - Revised guidelines for the management of non-ST-segment elevation acute coronary syndromesDebabrata Mukherjee
Division of Cardiology, University of Michigan Health System, 3910 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48103, USA
Curr Cardiol Rep 5:289-95. 2003..An optimal single strategy encompassing most patients' needs is not clear. This review focuses on the revised American College of Cardiology/American Heart Association guidelines for the management of patients presenting with UA/NSTEMI... - Clinical perspectives on the role of anti-platelet and statin therapy in patients with vascular diseasesSujoya Dey
Division of Cardiology, University of Michigan, Ann Arbor, Michigan 48109-0311, USA
Curr Vasc Pharmacol 1:329-33. 2003..Appropriate use of these agents may significantly decrease the cardiovascular morbidity and mortality of patients with PAD... - Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein<or=80 mg/dlThomas T Tsai
Department of Internal Medicine, Division of Cardiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Am J Cardiol 96:1491-3. 2005..0% vs 9.5%, p=0.005). These results suggest that patients who have an acute coronary syndrome and a low-density lipoprotein cholesterol level<or=80 mg/dl in the absence of statin therapy may benefit from such therapy at discharge... - Effects of cilostazol in patients with Raynaud's syndromeSanjay Rajagopalan
Division of Cardiology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Am J Cardiol 92:1310-5. 2003..018). Cilostazol increased conduit vessel diameter in patients with primary and secondary RS, with a favorable impact on conduit vessel responsiveness to cold in patients with primary RS without affecting microvascular flow or symptoms... - Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximabDebabrata Mukherjee
University of Michigan Health System, Ann Arbor, Michigan, USA
Am J Cardiol 90:1198-203. 2002..As in the overall trial, combination therapy in patients who underwent prior CABG led to a consistent reduction in key secondary complications of AMI, including recurrent ischemia and a trend toward reduced urgent revascularization... - Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trialsMarco Roffi
Division of Cardiology, University Hospital, Zurich, Switzerland
Circulation 106:3063-7. 2002..In the absence of mechanical emboli protection, this procedure is associated with high incidence of death and nonfatal ischemic events... - Gene therapy in cardiovascular diseasesKamala P Tamirisa
Division of Cardiology, The University of Michigan, Ann Arbor, Michigan 48109-0306, USA
Curr Gene Ther 2:427-35. 2002..This review discusses newer modalities of therapy for this subset, including therapeutic angiogenesis with growth factors and cell transplantation... - Clinical problem-solving. Double jeopardyBrahmajee K Nallamothu
Health Services Research and Development Center of Excellence, Ann Arbor Veterans Affairs Medical Center, and the Department of Internal Medicine, University of Michigan, Ann Arbor, USA
N Engl J Med 353:75-80. 2005 - Prognostic implication of troponin I elevation after percutaneous coronary interventionBrahmajee K Nallamothu
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
Am J Cardiol 91:1272-4. 2003 - Impact of extracardiac vascular disease on acute prognosis in patients who undergo percutaneous coronary interventions (data from the Blue Cross & Blue Shield of Michigan Cardiovascular Consortium [BMC2])Debabrata Mukherjee
University of Michigan Health System, Ann Arbor, Michigan, USA
Am J Cardiol 92:972-4. 2003..The underlying cause of this significant association is unclear, but it warrants further investigation in an attempt to improve outcome in this high-risk cohort... - Carotid artery stenting vs. endarterectomyMarco Roffi
Interventional Cardiology Unit, Division of Cardiology, University Hospital, Rue Micheli du Crest 24, Geneva, Switzerland
Eur Heart J 30:2693-704. 2009..Until further data become available, the performance of CAS should be limited to protocols or centres of excellence and targeted especially to patients at high risk for surgery... - Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularizationD Mukherjee
Department of Cardiology, University of Michigan, USA
Am Heart J 142:72-4. 2001..5% rate of myocardial infarction (15 of 59), and a mortality rate of 16.9% (10 of 59). CONCLUSIONS: The prognosis of many patients eligible for newer methods of revascularization on maximal medical therapy is poor... - Clinical association between renal insufficiency and positive troponin I in patients with acute coronary syndromeWisam Al Badr
Division of Internal Medicine, St. Joseph Mercy Oakland, Pontiac, Mich, USA
Cardiology 102:215-9. 2004..CONCLUSIONS: This large cohort study demonstrates that there appears to be no association between RI and positive TnI in patients with ACS... - Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)James B Froehlich
University of Michigan Health System, Ann Arbor, MI, USA
Am Heart J 151:1123-8. 2006..Given the poorer hospital outcomes in patients with PAD, our findings suggest considerable opportunity to improve care for these high-risk patients... - Potential impact of the HIPAA privacy rule on data collection in a registry of patients with acute coronary syndromeDavid Armstrong
Division of Cardiovascular Medicine, Department of Internal Medicine, and the Cardiovascular Center of the University of Michigan Health System, and Health Services Research and Development Center of Excellence, Ann Arbor, USA
Arch Intern Med 165:1125-9. 2005..50 annually thereafter. CONCLUSIONS: The HIPAA Privacy Rule significantly decreases the number of patients available for outcomes research and introduces selection bias in data collection for patient registries... - Implementation of the ACC/AHA guidelines for preoperative cardiac risk assessment in a general medicine preoperative clinic: improving efficiency and preserving outcomesYassar Almanaseer
The Michigan Cardiovascular Research and Reporting Program, University of Michigan, Ann Arbor, Mich, USA
Cardiology 103:24-9. 2005.... - Cardiac risk in noncardiac surgeryD Mukherjee
Division of Cardiology, University of Michigan Health System, University Hospital, Ann Arbor, MI, USA
Minerva Cardioangiol 50:607-19. 2002..Finally, the goal of appropriate preoperative evaluation and therapy should be to not only improve immediate periprocedural outcomes but should also be geared towards improved long term clinical outcome... - Shelf-price agreements: the next frontier in competitive bidding for coronary intervention suppliesRobert K Keast
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109-0311, USA
J Cardiovasc Manag 16:27-30. 2005..The results suggest that this strategy can further reduce supply costs while maintaining collaborative relationships with vendors... - Coronary revascularization prior to elective vascular surgery: does it reduce cardiac risk?Debabrata Mukherjee
Division of Cardiology, University of Michigan Health System, Ann Arbor, 48103, USA
J Vasc Surg 36:644-5. 2002 - Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modificationDebabrata Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor, Mich, USA
Am Heart J 144:753-9. 2002..In addition, the effects of various lifestyle modifications and therapeutic agents on intimal-medial thickness and cardiovascular end points are evaluated... - Pharmacogenomics in cardiovascular diseasesDebabrata Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor, USA
Prog Cardiovasc Dis 44:479-98. 2002..The goal of pharmaco-genomics is customization of drug therapy with administration of a medication in an optimum dose that will be safe and effective with reduction in morbidity and mortality... - Perioperative cardiac assessment for noncardiac surgery: eight steps to the best possible outcomeDebabrata Mukherjee
University of Michigan, Ann Arbor, USA
Circulation 107:2771-4. 2003 - Pharmacogenomics in cardiovascular diseasesDebabrata Mukherjee
Division of Cardiology, University of Michigan, Ann Arbor, MI, USA
Curr Probl Cardiol 28:317-47. 2003 - Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favorDebabrata Mukherjee
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536 0200, USA
Thromb Haemost 96:407-12. 2006.... - Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularizationPranab Das
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky and the VA Medical Center, Lexington, Kentucky 40536-0200, USA
J Invasive Cardiol 18:405-8. 2006..However, in ESRD patients undergoing coronary revascularization, DES use is effective in reducing 9-month TVR and the composite of death, MI and TVR... - Heparin-induced thrombocytopenia and cardiovascular diseasesPranab Das
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536-0200, USA
Am Heart J 152:19-26. 2006 - Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization eraMehdi H Shishehbor
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Am J Cardiol 97:1585-90. 2006..A randomized trial comparing multivessel PCI with staged or surgical revascularization is warranted... - Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS)Sanjay Rajagopalan
Division of Cardiovascular Medicine, 473 W 12th Ave, Ohio State University, Columbus, OH 43202, USA
Circulation 114:1914-22. 2006..The aims of the present study were to describe the prevalence of peripheral arterial disease (PAD) and its effects on prognosis and health-related quality of life (HRQOL) in an international cohort of patients on hemodialysis... - Current endovascular treatment of peripheral arterial diseaseH M Mardikar
Spandan Heart Institute and Research Center, Nagpur, India
Prog Cardiovasc Nurs 22:31-7. 2007..In this article, the authors review the current state of interventional treatment for peripheral arterial disease... - Endovascular treatment of carotid artery aneurysms with stent graftsDebabrata Mukherjee
Cleveland Clinic Foundation, Dept. of Cardiology, F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
J Invasive Cardiol 14:269-72. 2002..Endovascular stent graft obliteration of carotid aneurysms appears safe, feasible and a less invasive option compared to surgical repair... - Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR studyDeepak L Bhatt
Cleveland Clinic, Department of Cardiovascular Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Am Heart J 154:137-43. 2007..We sought to determine whether peroxisome proliferator-activated receptor gamma agonists had any beneficial effect on patients with metabolic syndrome undergoing percutaneous coronary intervention (PCI)... - Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events)Debabrata Mukherjee
Gill Heart Institute and the University of Kentucky, Lexington, Kentucky, USA
Am J Cardiol 100:1-6. 2007..In conclusion, outcomes after ACS are worse in patients with PAD or stroke, with the highest risk in patients with the 2 conditions and the use of evidence-based therapies are associated with improved outcomes in all ACS subgroups... - Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) studyH M Mardikar
Spandan Heart Institute, Nagpur, India
Am Heart J 154:344.e1-5. 2007..The objective of this study was to test several antiplatelet regimens in elective high-risk PCI patients by comparing different combinations of glycoprotein IIb/IIIa inhibitors and clopidogrel... - Acute coronary syndromes: unstable angina/non-ST elevation myocardial infarctionRohit Bhatheja
Gill Heart Institute, Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY 40536 0200, USA
Crit Care Clin 23:709-35, v. 2007..The last few years also have seen significant advances in antiplatelet and antithrombotic therapies for the management of patients who have acute coronary syndrome... - Current status of carotid stentingJi Sun Kim
Department of Internal Medicine, University of Kentucky, Lexington, Kentucky 40536 0200, USA
Curr Vasc Pharmacol 6:143-7. 2008..We review the available studies on carotid stenting and discuss appropriate use of this procedure. Emphasis is also placed on optimal long-term pharmacotherapy in patients with carotid stenosis... - Ischemia, revascularization, and perioperative troponin elevation after vascular surgeryDebabrata Mukherjee
J Am Coll Cardiol 44:576-8. 2004 - Hormone replacement therapy and secondary cardiovascular prevention: a meta-analysis of randomized trialsLeslie Cho
Loyola University Medical Center Maywood, Ill, USA
Cardiology 104:143-7. 2005..The purpose of this study was to assess the benefits and risks of HRT for prevention of cardiovascular events by conducting a meta-analysis of all randomized trials of HRT, and estimate cardiovascular event rates... - Feasibility of simultaneous bilateral carotid artery stentingMichael S Chen
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Catheter Cardiovasc Interv 61:437-42. 2004..There were no procedural deaths, myocardial infarctions, or strokes. Thus, among carefully selected patients, simultaneous bilateral carotid artery stenting is a promising, technically feasible option... - Cardiac overexpression of myotrophin triggers myocardial hypertrophy and heart failure in transgenic miceSagartirtha Sarkar
Department of Molecular Cardiology, Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
J Biol Chem 279:20422-34. 2004..Knowledge of the changes that take place as a result of overexpression of myotrophin at both the cellular and molecular levels will suggest novel strategies for treatment to prevent hypertrophy and its progression to heart failure... - Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE)Mark I Furman
Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass 01655, USA
Am Heart J 147:42-8. 2004..To examine the association between elevated leukocyte count and hospital mortality and heart failure in patients enrolled in the multinational, observational Global Registry of Acute Coronary Events (GRACE)... - Improving quality of care in the real world: efficacy versus effectiveness?Debabrata Mukherjee
Am Heart J 146:946-7. 2003 - Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patientsDebabrata Mukherjee
Division of Cardiovascular Medicine, University of Kentucky, 900 S Limestone Street, 326 Wethington Building, Lexington, KY 40536 0200, USA
Cardiol Clin 23:185-91. 2005..3). It seems prudent to consider CABG with LIMA grafting in diabetic patients who have severe multi-vessel disease and to consider angioplasty in selected patients who have more discrete and less severe disease... - Drug-drug interactions involving antiplatelet agentsEric R Bates
Eur Heart J 24:1707-9. 2003 - A 40-year-old female with exertional anginaDebabrata Mukherjee
University of Kentucky, Department of Cardiovascular Medicine, 326 Wethington Building, 900 S. Limestone, Lexington, KY, 40536, USA
J Invasive Cardiol 17:185-6. 2005 - Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survivalFernando A Cura
Department of Cardiology, Instituto Cardiovascular de Buenos Aires, Argentina
Am J Cardiol 91:587-90. 2003 - Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-upDebabrata Mukherjee
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0200, USA
Eur Heart J 26:2524-8. 2005..We report here the 1-year mortality of the study population... - Comparison of results of carotid stenting followed by open heart surgery versus combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure)Khaled M Ziada
Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
Am J Cardiol 96:519-23. 2005..CS may be a safer carotid revascularization option for this challenging patient population... - Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitorsDebabrata Mukherjee
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Arthritis Res Ther 5:8-11. 2003..The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors... - Aortic dissection--an updateDebabrata Mukherjee
Cardiac Catheterization Laboratories, University of Kentucky, KY, USA
Curr Probl Cardiol 30:287-325. 2005..Overall patients with aortic dissection are at high risk for an adverse outcome and need to be managed aggressively in hospital and long term with frequent follow-up... - Current role of antithrombotic agents in the treatment of acute coronary syndromesDebabrata Mukherjee
Tyler Gill Professor of Interventional Cardiology, Division of Vascular Medicine, Gill Heart Institute, University of Kentucky, Lexington 40536 0200, USA
Semin Thromb Hemost 30:627-32. 2004..We review two classes of antithrombotic drugs, the LMWHs and the DTIs and discuss their current roles in the management of patients with ACS... - Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?Debabrata Mukherjee
Gill Heart Institute, Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536-0200, USA
J Interv Cardiol 21:118-21. 2008 - Nonsteroidal anti-inflammatory drugs and the heart: what is the danger?Debabrata Mukherjee
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0200, USA
Congest Heart Fail 14:75-82. 2008..Physicians should consider patterns of risk and benefit in selecting the most appropriate agent for individual patients based on the individual gastrointestinal and cardiovascular risk profile... - Carotid brachytherapy for in-stent restenosisAlbert W Chan
Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
Catheter Cardiovasc Interv 58:86-92. 2003..We report our initial experience with brachytherapy for the treatment of restenosis after carotid stenting...